Background The activation of neurohumoral compensatory mechanisms is a common physiological phenomenon in heart failure in order to make up for a failing heart, which will usually have a deteriorating effect on overall health condition. Many medications,
Kawa Dizaye, Rojgar H. Ali
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala +1 more
wiley +1 more source
Congestion, decongestion, renal function and diuretics in (ESC) heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus +2 more
wiley +1 more source
EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
Aim. To study the effect of sacubitril/valsartan compared with valsartan on natriuresis, diuresis, blood pressure (BP) and the level of biomarkers in hypertensive patients.Material and methods.
Zh. D. Kobalava +3 more
doaj +1 more source
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure [PDF]
Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or ...
Aimo, Alberto +15 more
core +1 more source
The natriuretic peptides system in the pathophysiology of heart failure. From molecular basis to treatment [PDF]
After its discovery in the early 1980s, the natriuretic peptide (NP) system has been extensively characterized and its potential influence in the development and progression of heart failure (HF) has been investigated.
Carnovali, Marino +2 more
core +1 more source
Background: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.
Dimitri Roustan +2 more
doaj +1 more source
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT [PDF]
Aims: In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization.
AlHabib +28 more
core +2 more sources
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. [PDF]
AIMS: We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40-49%].
Borlaug +25 more
core +2 more sources
Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis [PDF]
Objective: The recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial suggested that implantable cardioverter defibrillators (ICDs) do not reduce overall mortality in patients ...
Beggs, Simon A.S. +4 more
core +1 more source

